Poxviral/retroviral chimeric vectors allow cytoplasmic production of transducing defective retroviral particles.
Defective vaccinia viruses were constructed that express functional Moloney murine leukemia virus-based vector genomes, giving rise to substantial titers of transduction-competent retrovirus particles after infection of a retroviral packaging cell line. For this purpose, the proviral retrovirus genome, engineered into the vaccinia virus mutant, was subjected to several modifications, including the replacement of retroviral promoter sequences by vaccinia virus sequences and the precise fusion of the transcription stop signal downstream of and the removal of such signals within the transcription unit, allowing cytoplasmic transcription of distinct full-length retroviral transcripts. Vaccinia-mediated expression of retroviral vector particles could be observed as early as 3 h postinfection and resulted in stable transduction of NIH/3T3 target cells at higher titers than the control performed by conventional plasmid transfections. Thus at least part of the vaccinia life cycle and retroviral assembly can occur concomitantly. Due to the favorable properties of vaccinia vectors, including high coding capacity, stability, and wide host range, defective vaccinia viral/retroviral chimeric vectors are promising tools for gene therapy applications.